Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽혜선 | * |
dc.date.accessioned | 2022-02-28T16:30:58Z | - |
dc.date.available | 2022-02-28T16:30:58Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 1473-5741 | * |
dc.identifier.other | OAK-30832 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/260776 | - |
dc.description.abstract | Reports on the association between the solute carrier organic anion transporter 1B1 (SLCO1B1) T521C polymorphism and methotrexate-induced hepatotoxicity in patients with malignancies are inconsistent. This meta-analysis evaluated the association between the SLCO1B1 T521C polymorphism and methotrexate-induced hepatotoxicity. We performed a systematic review of previous reports from the PubMed, Web of Science, and EMBASE databases, and a meta-analysis was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated to evaluate the effect of the SLCO1B1 T521C polymorphism on the occurrence of methotrexate-induced hepatotoxicity. In total, data from five studies including 465 patients were analyzed. Patients had received a high-dose methotrexate regimen (1-5 g/m2). The SLCO1B1 variant allele (C allele) carriers had a 1.9-fold higher risk of hepatotoxicity than wild-type homozygote carriers (TT; OR, 1.94; 95% CI, 1.14-3.31). This meta-analysis demonstrated that C allele carriers of the SLCO1B1 polymorphism had a higher risk of hepatotoxicity than patients with the TT genotype. The SLCO1B1 T521C polymorphism may be a useful predictor for methotrexate-induced hepatotoxicity in patients with malignancies. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. | * |
dc.language | English | * |
dc.publisher | NLM (Medline) | * |
dc.title | Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: a systematic review and meta-analysis | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 33 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 75 | * |
dc.relation.lastpage | 79 | * |
dc.relation.journaltitle | Anti-cancer drugs | * |
dc.identifier.doi | 10.1097/CAD.0000000000001125 | * |
dc.identifier.wosid | WOS:000780317000017 | * |
dc.identifier.scopusid | 2-s2.0-85122714434 | * |
dc.author.google | Han J.M. | * |
dc.author.google | Choi K.H. | * |
dc.author.google | Lee H.H. | * |
dc.author.google | Gwak H.S. | * |
dc.date.modifydate | 20240422115307 | * |